摘要
目的：探讨磷酸肌酸联合免疫球蛋白治疗小儿病毒性心肌炎的临床疗效及不良反应。方法：选取2011年9月至2015年1月我院收治的病毒性心肌炎患儿104例,采用随机数字表法分为治疗组和对照组各52例,均给予吸氧、纠酸、强心、利尿、抗感染、营养心肌等常规治疗。治疗组在常规治疗基础上给予静脉注射用人免疫球蛋白（每日0.05~0.15 m L/kg,最大剂量6 m L）和磷酸肌酸钠（每次0.5~1.0 g,每日1次）静脉滴注,疗程14 d。观察两组临床疗效,肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、肌钙蛋白（c Tn I）、乳酸脱氢酶（LDH）、天冬氨酸氨基转移酶（AST）水平,心肌酶谱恢复时间、临床症状消失时间及不良反应。结果：治疗组总有效率96.15%,高于对照组的75.00%（P〈0.05）。治疗后,两组CK、CK-KB、c Tn I、LDH、AST水平均较治疗前降低（P均〈0.05）,且治疗组上述指标均低于对照组（P均〈0.05）。治疗组心肌酶谱恢复时间、临床症状消失时间均短于对照组（P均〈0.05）。两组均未见明显不良反应。结论：磷酸肌酸联合免疫球蛋白治疗小儿病毒性心肌炎安全有效。
Objective： To investigate the clinical efficacy and the adverse reaction of phosphcreatine combined with immunoglobulins in the treatment of pediatric viral myocarditis. Methods： One hundred and four cases of patients with pediatric viral myocarditis were divided into the treatment group （n=52） and the control group （n = 52 ） according to the random number table method. The control group was treated with basic therapy and the treatment group was treated with phosphoereatine combined with immunoglobulins on the basis of basic therapy. Both groups received treatment for 14 days. The clinical efficacy, the levels of CK, CK-MB, cTnI, LDH, AST, the recovery time of the myocardial enzyme, the time of symptoms vanished and side reactions of the drug were observed. Results： The total effective rate of clinical efficacy in treatment group （96.15%） was significantly higher than that of the control group （75.00%） （P〈0.05）. After treatment, the levels of CK, CK-MB, eTnI, LDH, AST in the two groups were lower than those before treatment （ P〈 0.05 ）, and the treatment group were lower than the control group （ P 〈 0. 05 ）. The recovery time of the myocardial enzyme, the time of symptoms vanished in treatment group were significantly shorter than those of the control group （P〈0. 05）. There were no obvious side reactions of the drug during the treatment course. Conclusion： The clinical efficacy of the phosphocreatine combined with the immunoglobulins in the treatment of the pediatric viral myocarditis is remarkable and there are no obvious side reactions of the drug.
出处
《儿科药学杂志》
CAS
2016年第10期24-26,共3页
Journal of Pediatric Pharmacy
